Abbott Reports Strong Q4 & Full-Year 2025 Results, Issues Positive 2026 Outlook

summarizeSummary

Abbott Laboratories announced robust fourth-quarter and full-year 2025 financial results, exceeding expectations with double-digit adjusted EPS growth and providing an optimistic financial outlook for 2026.

check_boxKey Events

• Strong Q4 and Full-Year 2025 Performance

  Abbott reported fourth-quarter adjusted diluted EPS of $1.50, reflecting 12 percent growth, and full-year 2025 adjusted diluted EPS of $5.15, reflecting 10 percent growth.

• Positive 2026 Financial Outlook

  The company projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint.

• Strategic Growth Initiatives

  Abbott highlighted its agreement to acquire Exact Sciences, expected to close in Q2 2026, and recent regulatory approvals for its Volt™ PFA System and TactiFlex™ Duo Ablation Catheter, expanding its medical device leadership.

• Consistent Dividend Growth

  Abbott declared its 408th consecutive quarterly dividend of $0.63 per share, marking 54 consecutive years of dividend increases.

auto_awesomeAnalysis

Abbott's latest earnings report demonstrates solid operational performance, with significant growth in adjusted earnings per share and organic sales. The company's positive 2026 guidance, including projected double-digit adjusted EPS growth, suggests continued momentum. Strategic advancements, such as the Exact Sciences acquisition and new product approvals in medical devices, further strengthen its market position and future growth prospects, particularly as the stock trades near its 52-week low.